Crystallization method and bioavailability

摘要

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

主权项

1. A crystalline molecular complex of zoledronic acid selected from the group consisting of:
a crystalline zoledronic acid, sodium zoledronate, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 1 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 2, a crystalline ammonium zoledronic acid salt and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 3 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 4, a crystalline zoledronic diammonia water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 17 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 18, a crystalline zoledronic acid, L-lysine, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 5 or 25, or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 6 or 26, a crystalline zoledronic acid, DL-lysine, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 7, 19, 21, or 23, or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 8, 20, 22, or 24, a crystalline zoledronic acid, zoledronic, DL-lysine, ethanol, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 9 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 10, a crystalline zoledronic acid, adenine, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 13 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 14, a crystalline zoledronic acid, nicotinamide, and water complex characterized by a powder x-ray diffraction pattern as shown in FIG. 11 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 12, and a crystalline zoledronic acid and glycine complex characterized by a powder x-ray diffraction pattern as shown in FIG. 15 or characterized by a Fourier transform infrared spectroscopy pattern as shown in FIG. 16.